UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB
(Mark One)

[X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
     ACT OF 1934

For the quarterly period ended    September 30, 2002
                               ----------------------------

[]   TRANSITION  REPORT  PURSUANT  TO  SECTION  13 OR  15(d)  OF THE  SECURITIES
     EXCHANGE ACT OF 1934

For the transition period from ________________ to _______________

Commission File No.     33-55254-09

                        Rocky Point Pharmaceuticals, Inc.
        (Exact name of Small Business Issuer as specified in its charter)

         NEVADA                                      87-0434293
------------------------------------        ---------------------------
(State or other jurisdiction of             (I.R.S. Employer
incorporation or organization)       Identification Number)

9350 South 150 East, Suite 900
         Sandy, Utah                                          84070
------------------------------------                 ------------------
(Address of principal executive offices)    (Zip Code)

Issuer's telephone number, including area code                (801) 617-2040
                                               ------------------------------

         Indicate by check mark whether the Issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Issuer
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [ ] No

         Indicate the number of shares outstanding of each of the Issuer's
classes of common stock, as of the latest practicable date.

             Class                          Outstanding as of September 30, 2002
-------------------------------------       ------------------------------------
$.001 PAR VALUE CLASS A COMMON STOCK                   1,000,000 SHARES

                                        1

<PAGE>



                         PART 1 - FINANCIAL INFORMATION

Item 1.  Financial Statements.

BASIS OF REPRESENTATION

General

         The accompanying unaudited financial statements have been prepared in
accordance with the instructions to Form 10-QSB and, therefore, do not include
all information and footnotes necessary for a complete presentation of financial
position, results of operations, cash flows and stockholders' (deficit) in
conformity with generally accepted accounting principles. In the opinion of
management, all adjustments considered necessary for a fair presentation of the
results of operations and financial position have been included and all such
adjustments are of a normal recurring nature. Operating results for the three
months ended September 30, 2002, are not necessarily indicative of the results
that can be expected for the year ending June 30, 2003.


                                        2

<PAGE>



                Rocky Point Pharmaceuticals, Inc. and Subsidiary
                          (A Development Stage Company)
                           CONSOLIDATED BALANCE SHEETS


<TABLE>
<CAPTION>
                                                                                September 30,                June 30,
                                                                                    2002                       2002
                                                                                 (Unaudited)                 (Audited)
                                                                           ----------------------    ---------------------
ASSETS
   CURRENT ASSETS
<S>                                                                        <C>                       <C>
     Cash in bank                                                          $                1,199    $                   0
                                                                           ----------------------    ---------------------

                                                   TOTAL CURRENT ASSETS                     1,199                        0

OTHER ASSETS
   Software (Note 4)                                                                            1                        1
                                                                           ----------------------    ---------------------

                                                                           $                1,200    $                   1
                                                                           ======================    =====================

LIABILITIES & (DEFICIT)
   CURRENT LIABILITIES
     Accounts payable                                                      $                  850    $               2,500
     Payable - related parties (Note 3)                                                   100,250                  105,050
                                                                           ----------------------    ---------------------

                                              TOTAL CURRENT LIABILITIES                   101,100                  107,550

   STOCKHOLDERS' (DEFICIT)
     Common Stock $.001 par value:
       Authorized - 100,000,000 shares
       Issued and outstanding 13,384,960 shares                                            13,385                   12,000
     Paid-in capital in excess of par                                                       7,314                        0
     Deficit accumulated during the
       development stage                                                                 (120,599)                (119,549)
                                                                           ----------------------    ---------------------

                                          TOTAL STOCKHOLDERS' (DEFICIT)                   (99,900)                (107,549)
                                                                           ----------------------    ---------------------

                                                                           $                1,200    $                   1
                                                                           ======================    =====================
</TABLE>


                 See Notes to Consolidated Financial Statements.

                                        3

<PAGE>



                Rocky Point Pharmaceuticals, Inc. and Subsidiary
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                             Three Months            5/7/2002
                                                                                                 Ended               (Date of
                                                                                             September 30,         inception) to
                                                                                                 2002                9/30/2002
                                                                                        ----------------------  ------------------
<S>                                                                                     <C>                     <C>
Net sales                                                                               $                    0  $                0
Cost of sales                                                                                                0                   0
                                                                                        ----------------------  ------------------

                                                                        GROSS PROFIT                         0                   0

General and administrative expenses                                                                      1,050              20,600
                                                                                        ----------------------  ------------------

                                                                            NET LOSS    $               (1,050) $          (20,600)
                                                                                        ======================  ==================

Basic and Diluted earnings per share
   Net (loss) per weighted average share                                                $                 (.00)
                                                                                        ======================

Weighted average number of common shares used to compute
   net income (loss) per weighted average share                                                     12,751,976
                                                                                        ======================
</TABLE>



                 See Notes to Consolidated Financial Statements.

                                        4

<PAGE>



                Rocky Point Pharmaceuticals, Inc. and Subsidiary
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                                             Three Months            5/7/2002
                                                                                                 Ended               (Date of
                                                                                             September 30,         inception) to
                                                                                                 2002                9/30/2002
                                                                                        ----------------------  ------------------
OPERATING ACTIVITIES
<S>                                                                                     <C>                     <C>
   Net income (loss)                                                                    $               (1,050) $          (20,600)
   Adjustments to reconcile net income (loss) to cash used
     by operating activities:
       Stock issued for expenses                                                                             0              12,000
       Changes in accounts payable                                                                      (1,650)                850
       Payable - related parties                                                                        (3,800)              1,250
                                                                                        ----------------------  ------------------

                                               NET CASH USED BY OPERATING ACTIVITIES                    (6,500)             (6,500)
                                                                                        ----------------------  ------------------

FINANCING ACTIVITIES
   Issuance of Regulation S common stock                                                                 7,699               7,699
                                                                                        ----------------------  ------------------

                                           NET CASH PROVIDED BY FINANCING ACTIVITIES                     7,699               7,699
                                                                                        ----------------------  ------------------

                                                 INCREASE IN CASH & CASH EQUIVALENTS                     1,199               1,199

Cash and cash equivalents at beginning of year                                                               0                   0
                                                                                        ----------------------  ------------------

                                            CASH & CASH EQUIVALENTS AT END OF PERIOD    $                1,199  $            1,199
                                                                                        ======================  ==================
</TABLE>


ADDITIONAL INFORMATION
   A payable of $1,000 was settled by issuing 1,000,000 shares of common stock
   to the note holder. Shares were issued at par on August 27, 2002. On May 7,
   2002, the Company acquired software valued at $100,000 in exchange for a note
   payable to a related entity in the same amount.


                 See Notes to Consolidated Financial Statements.

                                        5

<PAGE>



                Rocky Point Pharmaceuticals, Inc. and Subsidiary
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                               September 30, 2002


NOTE 1:    CHANGE IN REPORTING ENTITY
           The statement of operations reflects the acquisition of Rocky Point
           Pharmaceuticals, Inc. ("Rocky Point") a reporting company under the
           Securities Act of 1934, by Luong Dae Solutions, Inc.,("Luong Dae") a
           development-stage company, on June 26, 2002 in a reverse acquisition,
           consummated by issuing 11,000,000 shares of common stock of Rocky
           Point to the founders of Luong Dae. Reverse acquisition accounting is
           appropriate since the shareholders of Luong Dae controlled
           approximately 92% of the outstanding common stock of Rocky Point
           immediately after the acquisition, and management of Luong Dae
           controlled the board of directors and day-to-day management of the
           Company after the acquisition. The reverse acquisition constitutes a
           change in reporting entity for accounting purposes. This reverse
           acquisition is considered to be a capital transaction (i.e. issuance
           of stock by Rocky Point accompanied by a recapitalization). The
           historical financial statements reflect the assets and liabilities of
           Luong Dae at their historical cost. Rocky Point had no assets on the
           date of the reverse acquisition. Rocky Point had liabilities of
           $7,550 on the date of the reverse acquisition. These liabilities have
           been charged to operations in the period ended June 30, 2002 as
           goodwill with no future value.

NOTE 2:    SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES
           Accounting Methods:
           The Company recognizes income and expenses based on the accrual
           method of accounting.

           Dividend Policy:
           The Company has not yet adopted any policy regarding payment of
           dividends.

           Cash and Cash Equivalents:
           For financial statement purposes, the Company considers all highly
           liquid investments with an original maturity date of three months or
           less when purchased to be cash equivalents.

           Estimates:
           The preparation of financial statements in conformity with generally
           accepted accounting principles requires management to make estimates
           and assumptions that affect the reported amounts of assets,
           liabilities, revenues and expenses during the reporting period.
           Estimates also affect the disclosure of contingent assets and
           liabilities at the date of the financial statements. Actual results
           could differ from these statements.

           Net Loss Per Share:
           Basic and diluted loss per share is computed by dividing net loss
           available to common shareholders by the weighted average number of
           common shares outstanding during the periods presented.

           Income Taxes:
           The Company utilizes the asset and liability method of accounting for
           income taxes as set forth in Statement of Financial Accounting
           Standards No. 109, "Accounting for Income Taxes" (SFAS 109). Under
           the asset and liability method, deferred taxes are determined based
           on the difference between the financial statement and tax bases of
           assets and liabilities using enacted tax rates in effect in the years
           in which the differences are expected to reverse. An allowance
           against deferred tax assets is recorded when it is more likely than
           not that such tax benefits will not be realized.

           At June 30, 2002 a deferred tax asset of about $3,700 has been fully
           reserved due to the Company's lack of operations to provide income to
           use the net operating loss carryover of $11,000 which expires as
           follows:

                  Year Ended                    Expires               Amount
            ----------------------      ----------------------     -------------
                 June 30, 2002               June 30, 2022         $      11,000
                                                                   -------------

                                                                   $      11,000

NOTE 2:    DEVELOPMENT STAGE COMPANY
           The Company was originally incorporated as Upsilon, Inc. under the
           laws of the State of Utah on April 14, 1986 and has been in the
           development stage since incorporation. On December 30, 1993, the
           Company was dissolved as a Utah corporation and reincorporated in
           Nevada as Upsilon Industries, Inc. On July 21, 1995, the Company
           changed its name to TTN Capitol, Inc., on October 15, 1995, the
           Company changed its name to Wasatch Pharmaceutical, Inc., and on May
           31, 2000 the Company changed its name to Rocky Point Pharmaceuticals,
           Inc. Luong Dae was incorporated on May 7, 2002 in Nevada, and became
           a subsidiary of the Company on June 26, 2002.


                                        6

<PAGE>



                Rocky Point Pharmaceuticals, Inc. and Subsidiary
                          (A Development Stage Company)
             NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (continued)
                               September 30, 2002



NOTE 3:    RELATED PARTY TRANSACTIONS
           The Company neither owns nor leases any real property. Office
           services are provided, without charge, by an officer. Such costs are
           immaterial to the financial statements, and, accordingly, have not
           been reflected therein. The officers and directors of the Company are
           involved in other business activities and may, in the future, become
           involved in other business opportunities. If a specific business
           opportunity becomes available, such persons may face a conflict in
           selecting between the Company and their other business interests. The
           Company has not formulated a policy for the resolution of such
           conflicts. At September 30, 2002 the Company owes $4,050 to a
           shareholder for expenses paid on behalf of the Company.

           At September 30, 2002, the Company owes $96,000 in royalties to
           Strategic Office Systems ("Strategic") in connection with the
           purchase of software. In addition, the Company owes Strategic $200 in
           penalties for failing to make the September 2002 royalty payment as
           agreed in the software purchase contract.

           Luong Dae is obligated to pay $450 for each copy and installation of
           software sold by Luong Dae. Luong Dae also agreed to pay $850 for
           each copy and installation of the software sold by Strategic. The
           minimum royalty is $2,000 per month.

NOTE 4:    SOFTWARE
           The Company purchased a software program from an entity controlled by
           its Vice President for $100,000. The transaction was recorded at a
           nominal value of $1. The excess of the consideration payable over the
           carrying value at the date of the transaction was recorded against
           accumulated deficit.

NOTE 5:    COMMON STOCK
           The Company issued 384,960 shares of "Regulation S" common stock on
           July 11, 2002. The Company received $7,699 from the sale, $385
           representing the par value of the stock and $7,314 attributable to
           paid-in capital in excess of par value.

           The Company issued 1,000,000 shares to settle a payable of $1,000 due
           to a former director of the Company. The shares were issued at par.

NOTE 6:    GOING CONCERN ITEMS
           The financial statements are presented on the basis that the Company
           is a going concern, which contemplates the realization of assets and
           the satisfaction of liabilities in the normal course of business over
           a reasonable length of time. At September 30, 2002, the Company has a
           working capital deficit of $99,901, and an accumulated deficit of
           $120,599. The Company has a substantial need for working capital.

           Management feels that loans from related parties and software sales
           will provide sufficient working capital to allow the Company to
           continue as a going concern.

NOTE 7:    SUBSEQUENT EVENTS
           On October 22, 2002, Arden Oliphant resigned as acting President,
           Secretary/Treasurer, and Director of the Company. Mark Timothy was
           subsequently named President, Secretary/Treasurer, and Director.

                                        7

<PAGE>



Item 2.  Management's Discussion and Analysis of Financial Condition and Results
         of Operations

         The Company has had no operational history and has yet to engage in
business of any kind. All risks inherent in new and inexperienced enterprises
are inherent in the Company's business. The Company has not made a formal study
of the economic potential of any business. At the present, the Company has not
identified any assets or business opportunities for acquisition. The only
activity for the period ended September 30, 2002 was the incurrence of costs
associated with periodic filings of required forms with the SEC.

         The Company has no liquidity and no presently available capital
resources, such as credit lines, guarantees, etc. and should a merger or
acquisition prove unsuccessful, it is possible that the Company may be dissolved
by the State of Nevada for failing to file reports. Should management decide not
to further pursue its acquisition activities, management may abandon its
activities and the shares of the Company would become worthless.

         Based on current economic and regulatory conditions, Management
believes that it is possible, if not probable, for a company like the Company,
without many assets or liabilities, to negotiate a merger or acquisition with a
viable private company. The opportunity arises principally because of the high
legal and accounting fees and the length of time associated with the
registration process of "going public". However, should any of these conditions
change, it is very possible that there would be little or no economic value for
anyone taking over control of the Company.

                           PART II - OTHER INFORMATION

Item 6.    Exhibits and Reports on Form 8-K

           (a)  Exhibits
                Exhibit 99.1 CEO Certification
                Exhibit 99.2 CFO Certification

           (b) Reports on Form 8-K
                An 8-K was filed on July 9, 2002 to announce the acquisition of
                Luong Dae Solutions, Inc. as a subsidiary. An 8-K was filed on
                August 14, 2002 to announce the change of year end to June 30.

                                   SIGNATURES

         Pursuant to the requirements of the Securities and Exchange Act of
1934, the Issuer has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                            Rocky Point Pharmaceuticals, Inc.



Dated: March 15, 2004         By:  /s/ Mark Timothy
      ----------------           --------------------------------
                              Mark Timothy, President,
                              Secretary/Treasurer, and Director

         Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.



Dated:  March 15, 2004         By:  /s/ Mark Timothy
       ----------------           --------------------------------
                               Mark Timothy, President,
                               Secretary/Treasurer, and Director


                                        8

<PAGE>



Exhibit 99.1 CEO Certification

In connection with the quarterly report on Form 10-QSB for the quarter ended
September 30, 2002 (Report), as filed with the Securities and Exchange
Commission, on the date hereof, the undersigned Chief Executive Officer of Rocky
Point Pharmaceuticals, Inc. (the "Company"), certifies to the best of my
knowledge, pursuant to 18 USC 1350, as adopted pursuant to ss.302 and
promulgated as 18 USC 1350 pursuant to ss.906 of the Sarbanes- Oxley Act of
2002, that:

 1.      The Report referenced above has been read and reviewed by the
         undersigned.

 2.      The Report fully complies with the requirements of Section 13(a) or
         15(d) of the Securities Exchange Act of 1934.

 3.      The Report referenced above does not contain any untrue statement of a
         material fact or omit to state a material fact necessary in order to
         make the statements made, in light of the circumstances under which
         such statements were made, not misleading.

 4.      I acknowledge that the management of the Company is solely responsible
         for the fair presentation in the financial statements of the financial
         position, results of operations and cash flows of the Company in
         conformity with accounting principles generally accepted in the United
         States of America.

Based upon my knowledge, the financial statements, and other such financial
information included in the report, fairly present the financial condition and
results of operations of the Company as of and for the period ended September
30, 2002.

In my opinion, the accompanying interim financial statements, prepared in
accordance with the instructions for Form 10-QSB, are unaudited and contain all
material adjustments, consisting only of normal recurring adjustments necessary
to present fairly the financial condition, results of operations and cash flows
of the Company for the respective interim periods presented. The current period
results of operations are not necessarily indicative of results which ultimately
will be reported for the full fiscal year.

Additionally, I acknowledge that the Company's Board of Directors and Management
are solely responsible for adopting sound accounting practices, establishing and
maintaining a system of internal control and preventing and detecting fraud. The
Company's system of internal accounting control is designed to assure, among
other items, that 1) recorded transactions are valid; 2) valid transactions are
recorded; and 3) transactions are recorded in the proper period in a timely
manner to produce financial statements which present fairly the financial
condition, results of operations and cash flows of the Company for the
respective periods being presented.

 /s/ Mark Timothy
Mark Timothy, President, CEO, and Director

Dated: March 15, 2004
       -------------------------------------


                                        9

<PAGE>


Exhibit 99.2 CFO Certification

In connection with the quarterly report on Form 10-QSB for the quarter ended
September 30, 2002 (Report), as filed with the Securities and Exchange
Commission, on the date hereof, the undersigned Chief Financial Officer of Rocky
Point Pharmaceuticals, Inc. (the "Company"), certifies to the best of my
knowledge, pursuant to 18 USC 1350, as adopted pursuant to ss.302 and
promulgated as 18 USC 1350 pursuant to ss.906 of the Sarbanes- Oxley Act of
2002, that:

1.       The Report referenced above has been read and reviewed by the
         undersigned.

2.       The Report fully complies with the requirements of Section 13(a) or
         15(d) of the Securities Exchange Act of 1934.

3.       The Report referenced above does not contain any untrue statement of a
         material fact or omit to state a material fact necessary in order to
         make the statements made, in light of the circumstances under which
         such statements were made, not misleading.

4.       I acknowledge that the management of the Company is solely responsible
         for the fair presentation in the financial statements of the financial
         position, results of operations and cash flows of the Company in
         conformity with accounting principles generally accepted in the United
         States of America.

Based upon my knowledge, the financial statements, and other such financial
information included in the report, fairly present the financial condition and
results of operations of the Company as of and for the period ended September
30, 2002.

In my opinion, the accompanying interim financial statements, prepared in
accordance with the instructions for Form 10-QSB, are unaudited and contain all
material adjustments, consisting only of normal recurring adjustments necessary
to present fairly the financial condition, results of operations and cash flows
of the Company for the respective interim periods presented. The current period
results of operations are not necessarily indicative of results which ultimately
will be reported for the full fiscal year.

Additionally, I acknowledge that the Company's Board of Directors and Management
are solely responsible for adopting sound accounting practices, establishing and
maintaining a system of internal control and preventing and detecting fraud. The
Company's system of internal accounting control is designed to assure, among
other items, that 1) recorded transactions are valid; 2) valid transactions are
recorded; and 3) transactions are recorded in the proper period in a timely
manner to produce financial statements which present fairly the financial
condition, results of operations and cash flows of the Company for the
respective periods being presented.

  /s/ Mark Timothy
Mark Timothy, Secretary/Treasurer, CFO, and Director

Dated: March 15, 2004
       ----------------------------------------------


                                       10